Strong and strong joint efforts, Novo Nordisk and China Resources pharmaceutical layout growth and development field.

On July 15, Novo Nordisk and China Resources Pharmaceuticals announced that, based on an earlier letter of intent signed by the two sides, Novo Nordisk and China Resources Pharmaceuticals' China Resources 39 Pharmaceutical Co., Ltd(hereinafter: China Resources 39) will jointly promote the recombinant human growth hormone injection Noze ® in Chinese mainland through a contract sales modelThe partnership, which will take effect on August 1, 2020, aims to further enhance the accessibility of Nozer ® in China and benefit more Chinese patientsData show that there are currently 39 million small population in China, the number of children in need of treatment between 4 and 15 years of age is about 7 million, and the number of people attending less than 300,000 patients a year, of which less than 30,000 patients are actually receiving treatment, the treatment rate is less than 1%Early signs of childhood dwarfism are often overlooked due to cognitive deficienciesParents tend to think that their child is just "late to develop" and miss treatment without attracting attentionAccording to the Recommendations for the Application of Pediatric Clinical Practice sedatiating of genetically recombinant human growth hormone, recombinant human growth hormone (rhGH) can effectively increase the growth rate of children with short statureIt is understood that Nozer ® is Noord's research and development and production of recombinant human growth hormone products, since 1966 from the pituitary hormone for first patients, Novo Nordisk has more than 50 years of successful experience in the field of growth hormoneHas been listed in more than 100 countries and regions, accumulated more than 30 years of global clinical experience and safety data, is the first use can be stored at 25 degrees C for 21 days of pre-filled water agent growth hormoneIn 2018, Nozer ® was approved for listing in ChinaAs of June 2020, Nozer ® is the only imported water-based growth hormone listed in China and is approved for use in growth disorders caused by inadequate production of growth hormone in children, growth disorders in girls due to stunting of gonads (Turner syndrome), pre-adolescent childhood growth retardation due to chronic kidney disease, small size in children due to Noonan syndrome, and adult growth hormone deficiencyThe NordiFlex ® ® NordiFlex comes in different sizes: 5mg, 10mg and 15mg, requiring no mixing and loading, and is easy to use, allowing self-injection in just three stepsAccording to the notice, the cooperation China Resources 39 will be responsible for the academic promotion of Nozer ® in the country, its wholly-owned subsidiary China Resources North Trade Pharmaceutical Management Co., Ltdwill be responsible for the specific implementationNovo Nordisk's headquarters remain the owner of Nozer ®, and the Listing LicenseE (MAH) will continue to be responsible for the production of Nozer's ® products, guide medical strategy and medical interaction, and support patients through a patient hotlineThe industry believes that, relying on Novo Nordisk's decades of innovation and experience in the field of recombinant human growth hormone, as well as China Resources Pharmaceuticals' excellent academic promotion capabilities and extensive business network in the field of pediatrics, the two sides will consolidate and expand Norze ®'s academic outreach network, further expand its accessibility, provide medical professionals with high-quality treatment options for more patients